In the Q&A at the BIO CEO & Investor Conference, Christoph Westphal mentioned that SRT501's future as a drugable treatment of Type 2 Diabetes may lie in the pairing of it with other drugs such as metamorfin. The NCE, which is 1,000 times more potent than SRT501, is viewed within the company as the better candidate for stand alone type 2 diabetes treatment. Data in the next few months should provide the information necessary to make this determination on SRT501.
Do your own DD.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment